Objective To determine whether microglial activity, measured using translocatorprotein positron emission tomographic imaging (PET), is increased in unmedicated subjects presenting with sub-clinical symptoms indicating they are at ultra high risk of psychosis, and to determine if it is elevated in schizophrenia after controlling for a translocator specific genetic polymorphism.
Introduction
Schizophrenia is a severe psychiatric disorder characterised by psychotic and cognitive symptoms, and is a leading cause of global disease burden (1) . It is generally preceded by a prodromal phase of attenuated psychotic symptoms and functional impairment (2) . Subjects meeting standardised criteria for this phase have an ultra high risk for developing a psychotic disorder, in most cases schizophrenia (3) . Approximately ~35% of high risk subjects will develop a psychotic disorder within 24 months (4).
Whilst the pathoaetiology of schizophrenia is not fully understood, there is increasing evidence for the involvement of neuroinflammatory processes. Microglia are the resident immune cells of the central nervous system and several lines of evidence indicate microglial involvement in the pathology of psychosis (5) (6) (7) . In ultra high risk subjects, there are elevations in the levels of pro-inflammatory cytokines (8) which are also elevated in patients with schizophrenia (9) . The levels of such peripheral markers have also been associated with the reductions in grey matter volume in both ultra high risk subjects (10) and patients with schizophrenia (11) . Post-mortem investigation of brain tissue has found elevated microglial cell density (with a hypertrophic morphology) in schizophrenia compared with controls (5), particularly in the frontal and temporal lobes (12) , although some studies have found no differences (13) . However, as microglial activity is dynamic, post-mortem studies may miss alterations early in the development of the disease.
Elevations in microglial activity can be measured in vivo with positron emission tomography (PET) using radioligands specific for the 18kD translocator-protein P e e r R e v i e w O n l y 6 (TSPO), which is expressed on microglia (14) . Investigations using the first generation radiotracer (R)- [ 11 C]PK11195 have revealed an increase in TSPO binding in medicated patients with schizophrenia when compared to healthy controls (6, 7).
The first investigation of microglia using PET in schizophrenia, in a cohort of 10 patients, revealed a total grey matter elevation of microglial activity in the five years following diagnosis (6) . The most recent investigation in seven chronically medicated patients with schizophrenia using (R)-[ 11 C]PK11195 demonstrated an elevation in hippocampal binding potential and a non-significant 30% increase in total grey matter binding potential (7) .
Whilst these studies indicate elevated microglial activity in schizophrenia, they included patients in whom the disorder was already established. It is therefore unknown whether this elevation predates the onset of, or becomes evident after, the first episode of frank psychosis.
Therefore in the present investigation we seek to determine whether microglial activity is elevated in ultra high risk subjects using the novel TSPO radioligand High affinity binders (HABs, C/C) have the greatest tracer affinity, low affinity binders (LABs , T/T) have a 50 fold reduction in affinity, and mixed affinity binders (MABs , C/T) express both HAB and LAB TSPO in approximately equal proportion (17) . In view of this we included a cohort of patients to test the hypothesis that TSPO binding is elevated in schizophrenia after adjusting for this polymorphism, as this has not been taken into account previously. We also tested the secondary hypothesis that there would be a positive relationship between total grey matter microglial activity and symptom severity.
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Methods
The study was approved by the local research ethics committee and was conducted in accordance with the Declaration of Helsinki. After complete description of the study to the subjects, written informed consent was obtained.
Subjects
A total of 56 subjects were recruited and completed the study; 14 subjects meeting ultra high risk criteria, as assessed on the comprehensive assessment of the at risk 3. Benzodiazepine use, whether prescribed or not (20) . One subject was excluded due to a positive result for benzodiazepines on the scan day.
4. History of head injury resulting in unconsciousness, or any physical medical condition associated with inflammation.
5. At the time of screening, subjects were tested for TSPO genotype to determine binding status (17) . Subjects with a LAB genotype were excluded.
6. In ultra high risk and control subjects: antipsychotic medication exposure.
7. Significant prior exposure to radiation 8. Pregnancy or breast feeding.
Healthy control subjects with a personal history of a psychiatric disorder or a first degree relative with schizophrenia or a psychotic illness were excluded.
Clinical and neuropsychological measures
At screening all subjects were assessed using the SCID (19) . Ultra high risk subjects
were assessed on the CAARMS (2) by a trained investigator and patients with a diagnosis of schizophrenia were assessed on the positive and negative syndrome were assessed using the Beck Depression Inventory (BDI) (22) .
PET imaging
An initial low dose transmission computer tomography (CT) scan (0. 
Image analysis
All PET images were corrected for head movement using nonattenuation-corrected images, as they include greater scalp signal, which improves re-alignment compared to attenuation-corrected images (25) . Frames were realigned to a single 'reference' space identified by the individual T1 MRI scan. The transformation parameters were then applied to the corresponding attenuation-corrected PET frames, creating a movement-corrected dynamic image for analysis. Regional time-activity curves Nevertheless, for completeness, we analysed the data using the 2TCM as well (see on-line supplemental information and Supplemental Table 1 ). Even after accounting for genotype, high inter-subject variability is seen in imaging with TSPO tracers. With PK11195 plasma protein binding is evident and may account for some levels of variability with TSPO imaging (27) . Indeed TSPO ligand quantification approaches mostly use tissue reference methodologies (28) . Analysis of PK11195 is conducted using simplified reference tissue models (SRTM) and supervised cluster analysis (29). This method is not applicable to second generation TSPO tracers, including PBR28, as the higher ligand affinity leads to appreciable endothelial binding in the blood brain barrier (BBB) (26) . As a result, it is not possible to identify a supervised cluster for reference. Our outcome measure therefore was the distribution volume ratio (DVR, the ratio of the ܸ ் in the ROI to ܸ ் in the whole brain) as this accounts for inter-subject variability in the input function. In secondary analyses, we tested the regional specificity of group changes by comparing DVR between groups in regions (the cerebellum and brainstem) where we did not expect marked inflammatory changes based on the post-mortem studies and grey matter changes seen in people at risk of psychosis (30) . To ensure nonspecific effects of normalization, our parameters used to normalize the PET signal were tested for group differences. There are no differences in blood or normalization regions used (see Supplemental Table 2 ). Demographic data and tracer activity data were analysed using independentsamples t-tests. Multiple analysis of covariance (ANCOVA) with Bonferroni correction (32) was used to determine whether there was an effect of group on [ 11 C]PBR28 binding associated microglial activity in the total grey matter, frontal lobe, and temporal lobe. There is data to suggest that cortical microglial density, hence TSPO binding, is elevated with aging (33), which is also evident in our data (see Supplemental Table 3 ). For this reason, we performed group level analysis using age as a covariate. There is a significantly higher binding of tracer in HABs than
Statistical analysis
MABs and the variation in signal from HAB and MAB subjects is high, with a large degree of overlap across the binding statuses (Supplemental Figure 3) .
Hence we pooled the binding statuses in our groups and co-varied for genotype in our analysis. (17) . For all statistical comparisons alpha was set at a 0.05 threshold (two-tailed) for significance. Statistical analysis was performed using SPSS 21 (IBM, USA). Partial correlation analysis was used to test the association of microglial activity with symptom severity and total grey matter volumes, with age and affinity as covariates of no interest. 
Results

Demographic Comparisons and Tracer Dosing
No significant demographic differences between the two groups of controls and respective patient groups were observed (Table 1 ). There were no differences in the injected dose, injected mass, specific activity, parent plasma fraction or plasma over blood ratio between ultra high risk subjects or patients with schizophrenia and their respective controls (Supplemental Table 4 ).
[ 11 C]PBR28 distribution in total grey matter regions
The Table 2 ). Secondary analysis to investigate regional specificity revealed no difference between ultra high risk or schizophrenia and respective controls in cerebellar or brainstem DVR (Table 2 ). Representative PET images of control, ultra high risk and patients with schizophrenia are presented in Figure 1 C. When comparing regions using V T , with either 2TCM or 2TCM-1K, no significant group difference was observed (supplemental Table 5 ). 
Genotype specific analysis
In further sensitivity analyses, we repeated the analyses separately for HABs and MABs in the UHR. This showed that the elevation in the ultra high subject was present irrespective of whether the analysis was restricted to HABs or MABs (Supplemental Table 6 and Supplemental Figure 3) .
Relationship between [ 11 C]PBR28 distribution and symptom severity
In ultra high risk subjects, there was a positive correlation between the total CAARMS symptom severity score and 
0.802).
In patients with schizophrenia, there was no significant correlation between total grey matter DVR and total PANSS score (Supplemental Figure 2) . There was no relationship between depressive symptom severity (Beck Depression Inventory 
Exploratory analysis of DVR normalization
To evaluate whether our findings were influenced by the signal used for normalization, we conducted exploratory analyses using the cerebellum and white matter as alternative normalization regions. Cerebellar normalization did not alter the major regional findings (frontal lobe p=0.001; temporal lobe the course of the prodromal period to determine if there is a change during the prodromal phase. As the ultra high risk subjects, who had recently presented to psychiatric services, were medication naïve and had no history of psychotic disorder, these findings cannot be attributed to effects of previous illness or its treatment.
p=0.006). White matter normalization performed similarly to the cerebellum (see supplemental table 7).
Interestingly, at the time of writing, one ultra high risk subject has transitioned to first episode psychosis. This subject had the highest total grey matter The present findings are consistent with recent evidence of elevated peripheral inflammatory markers in people at high risk of psychosis (8, 10) , and suggest that elevated microglial activity predates the onset of frank psychosis. We also found evidence of elevated microglia activity in people with schizophrenia relative to controls with a large effect size (Cohen's d >1.7). This extends previous PET studies This may be due to the fact that these patients were not acutely unwell.
Limitations
Antipsychotic treatment is a potential confound in the schizophrenia group (see Supplemental Table 6 ) but not the ultra high risk group. There is growing evidence to suggest an influence of antipsychotic medication on microglial cell dynamics, including evidence that antipsychotics may reduce microglial activity (36) (37) (38) . Hence in future studies it would be preferable to investigate patients with schizophrenia who were medication naïve.
In this investigation, we have used an approach to analysis (accounting for endothelial and vascular binding), which has been shown to be more reliable than alternative approaches (26) . This was applied in a standardized automated manner across groups, and also applied to control regions (brain stem and cerebellum) to examine the specificity for our findings. A limitation of all current approaches to imaging microglia, including with [ 11 C]PBR28, is that the outcome measure is V T . Thus the elevation in grey matter could reflect increased In our sample, plasma input analysis results in a ~30% level of V T variability using the 2TCM approach. This variability is due in part to a small free fraction (f p ), which has been reported to introduce 29% variability (see Supplemental   Table 8 and (26)). This being the case, the noise and measurement error from f p appears to be greater than the component it represents (40) relatively low. However this noise would obscure a difference between groups, so is unlikely to account for our findings. In this study we did not correct for possible partial volume effects. Given that brain volume is generally reduced in schizophrenia, these would tend to underestimate the elevations observed here and not account for our group differences. There is a relatively higher binding in control subjects matched to patients with schizophrenia over those matched to the ultra high risk group. This can be explained in part by age associated increases in TSPO but also by an increased number of MABs in the ultra high risk matched controls. Finally, it is important to note that not all the ultra high risk subjects will go on to develop a psychotic disorder and we will conduct clinical follow-up to determine whether the elevated microglial activity is specific to the development of the disorder or risk factors for psychosis.
Implications
Whilst TSPO may be expressed on astrocytes (50) and some neuronal sub-types (51) , it is predominantly expressed on microglia (52) . The direct biological relationship between microglia and TSPO binding in vivo is not fully understood.
However, in non-human primates inflammation induced increases in microglial activity cause marked increases in [
11 C]PBR28 signal, confirmed post mortem to be largely due to microglial binding (53) . Microglia perform immune surveillance roles, mount inflammatory response to injury (54) and are involved in synaptic modulation in experience dependent plasticity (55) . Interpretation of elevated activity is therefore complex and not defined by 'activated' or 'resting'. The elevations presented here When our findings are interpreted with evidence that anti-inflammatory drugs are effective in schizophrenia (57) , particularly in addressing early negative symptoms (58), they suggest a neuroinflammatory process is involved in the development of psychotic disorders. Whilst this indicates that anti-inflammatory treatment may be effective in preventing the onset of the disorder, further studies are required to determine the clinical significance of elevated microglial activity.
Conclusions
Here we provide, to our knowledge, the first evidence of elevated brain microglial activity in people at ultra high risk of psychosis, and show that greater microglial activity is associated with greater symptom severity. We also demonstrate the first in vivo elevations of TSPO binding in schizophrenia with a second generation tracer after adjusting for TSPO genotyping. These findings are consistent with increasing evidence that that there is a neuroinflammatory component in the development of psychotic disorders, raising the possibility that it plays a role in its pathogenesis. Highlighted subject, transition case.
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Symptom scales measured in high risk subjects on the CAARMS (comprehensive assessment of the 'at risk mental state') and in schizophrenia on the PANSS (positive and negative syndrome scale). 
